On the evening of January 22, Johnson & Johnson, Legend Biotech's partner company, mentioned in its 2024 performance that the annual sales of Cilta-cel reached $963 million, increasing by 92.7% from $500 million in sales for 2023, making it the fastest-growing product in its innovative pharmaceuticals business.This also means that Cilta-cel is only one step away from becoming the next domestically produced "billion-dollar molecule."Ciltacabtagene Autoleucel (Brand Name: CARVYKTI) is a chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), jointly developed by Legend Biotech and Janssen, a subsidiary of Johnson & Johnson.February 2022,Cilta-celApproved for marketing by the U.S. FDA.In 2024, Cilta-cel was successfully approved in China, becoming the sixth CAR-T product to be launched in the Chinese market. The price of Cilta-cel after its launch in the United States was $465,000 per dose, but Legend Biotech has not yet disclosed its pricing in China.
For reference, apart from Cilta-cel, the pricing of the other five CAR-T products that have been approved for marketing in China ranges from 999,000 yuan to 1.29 million yuan.Pharmaceutical ResearchReportSharing CampCollect and Share Mainstream Pharmaceutical Research Reports in the Entire Market
Only 0.8 yuan per day
EnjoyMore than 2000 articlesSelected Medical Research Reports
New additions each yearAdditional 500 Articles
